首页> 美国卫生研究院文献>Cancers >Extracellular Vesicles in Diagnosis and Treatment of Pancreatic Cancer: Current State and Future Perspectives
【2h】

Extracellular Vesicles in Diagnosis and Treatment of Pancreatic Cancer: Current State and Future Perspectives

机译:细胞外囊泡在胰腺癌的诊断和治疗中的研究:现状与未来

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Pancreatic cancer remains one of the deadliest diagnoses a patient can receive. One of the reasons for this lethality is that this malignancy is often detected very late due to a lack of symptoms during the early stages. In addition to the lack of symptoms, we currently do not have a reliable biomarker for screening. Carbohydrate antigen (CA) 19-9 has a sensitivity between 79% and 84% and a specificity of 82–90%, making it unreliable for early detection. Recently, there have been numerous studies on the use of extracellular vesicles (EVs) to detect pancreas cancer. This field has been rapidly expanding, with new methods and biomarkers being introduced regularly. This review provides a systematic update on the commonly used and promising methods used in the detection of EVs, biomarkers associated with EVs for early detection and prognosis, as well as studies looking at using EVs as therapeutics. The review ends with remarks about areas to focus on using EVs going forward.
机译:胰腺癌仍然是患者可以接受的最致命的诊断之一。这种致死性的原因之一是,由于早期缺乏症状,这种恶性肿瘤通常很晚才被发现。除缺乏症状外,我们目前尚无可靠的生物标志物用于筛查。碳水化合物抗原(CA)19-9的敏感性介于79%和84%之间,特异性为82-90%,使其不可靠地进行早期检测。近来,关于使用细胞外囊泡(EV)检测胰腺癌的研究已经很多。该领域正在迅速扩展,定期引入新方法和生物标记。这篇综述提供了在检测电动汽车,与电动汽车相关的生物标志物以进行早期检测和预后以及将电动汽车用作治疗方法的研究方面常用和有前途的方法的系统更新。回顾以关于未来重点关注电动汽车的领域的评论结束。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号